<DOC>
	<DOCNO>NCT00803231</DOCNO>
	<brief_summary>The transparency commission wish laboratory Lilly France set follow-up study describe condition use Xigris® France . The purpose study describe characteristic treat patient , condition drug use , particular condition treatment initiation clinical development patient normal clinical practice , particular rate cause mortality within one month .</brief_summary>
	<brief_title>Follow-up Data Patients Treated With XIGRIS® France</brief_title>
	<detailed_description>The objective study define specific requirement Transparency Commission follow : - To describe characteristic patient treat Xigris® - socio-demographic characteristic , - clinical profile - To determine condition use Xigris® - To describe previous treatment , - To observe delay Xigris® initiation , - To describe dose , duration treatment , - To study concomitant treatment associate treatment - To describe clinical evolution patient - To observe mortality 1 month - To describe reason death</detailed_description>
	<mesh_term>Drotrecogin alfa activate</mesh_term>
	<criteria>Patients eligible include study meet follow criterion Patients treat Xigris® study period intensive care unit France Patients minimum age 18 year Patients present normal course care</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>